SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
79,400
-4,000 (-4.80%)
Sep 11, 2026, 3:30 PM KST

SK Biopharmaceuticals Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
379,968307,771322,807239,700104,060225,922
Short-Term Investments
1,9051,7111,6821,418201,394108,417
Cash & Short-Term Investments
381,873309,482324,489241,118305,454334,339
Cash Growth
71.55%-4.63%34.58%-21.06%-8.64%-13.83%
Accounts Receivable
311,596228,826173,819111,00163,50655,883
Other Receivables
1,619450.84433.792,6412,9451,477
Receivables
313,214229,276174,253113,64266,45157,360
Inventory
96,127100,240111,679102,52590,92051,933
Prepaid Expenses
72,73328,90530,12525,89818,73420,964
Other Current Assets
14,29915,32610,8255,5386,3666,622
Total Current Assets
878,247683,229651,371488,722487,925471,219
Property, Plant & Equipment
57,37960,51043,93247,75320,35022,938
Long-Term Investments
87,56766,00291,439104,09199,959107,665
Goodwill
1,7731,6501,6913,392--
Other Intangible Assets
16,5085,3388,87514,54217,18118,900
Long-Term Deferred Tax Assets
327,430325,775206,40044,72329,64118,919
Long-Term Deferred Charges
37,40944,22721,9639,090--
Other Long-Term Assets
12,32911,52611,05910,7719,1073,985
Total Assets
1,418,7651,198,3091,036,811723,171664,241643,652

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
7,7829,3373,4032,34623,10616,931
Accrued Expenses
76,22994,63779,65371,33155,03564,776
Short-Term Debt
---50,000--
Current Portion of Long-Term Debt
--150,715-0--
Current Portion of Leases
9,0018,4297,0917,0615,6445,481
Current Income Taxes Payable
2,7162,100451.8288.78208.361,997
Other Current Liabilities
227,578180,697154,962110,79279,07959,120
Total Current Liabilities
323,305295,200396,276241,619163,073148,306
Long-Term Debt
---94,484143,722-
Long-Term Leases
39,82640,49126,67626,5056,53010,256
Pension & Post-Retirement Benefits
-----52.72
Long-Term Deferred Tax Liabilities
---1,909--
Other Long-Term Liabilities
33,87236,34939,87437,70334,35640,850
Total Liabilities
397,004372,039462,827402,219347,681199,465

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
39,15739,15739,15739,15739,15739,157
Additional Paid-In Capital
1,089,3201,084,8481,084,8481,084,8481,084,8481,084,848
Retained Earnings
-164,143-354,142-621,532-861,561-827,555-689,141
Comprehensive Income & Other
57,42743,17343,80021,24320,1129,325
Total Common Equity
1,021,761813,036546,273283,686316,560444,187
Minority Interest
-13,23427,71137,265--
Shareholders' Equity
1,021,761826,270573,984320,951316,560444,187
Total Liabilities & Equity
1,418,7651,198,3091,036,811723,171664,241643,652

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
48,82748,920184,482178,050155,89615,738
Net Cash (Debt)
333,046260,562140,00763,068149,558318,602
Net Cash Growth
125.62%86.11%121.99%-57.83%-53.06%-13.78%
Net Cash Per Share
4252.403327.181787.78805.331909.744068.30
Filing Date Shares Outstanding
78.3178.3178.3178.3178.3178.31
Total Common Shares Outstanding
78.3178.3178.3178.3178.3178.31
Working Capital
554,942388,029255,095247,104324,852322,914
Book Value Per Share
13047.1010381.846975.493622.464042.235671.93
Tangible Book Value
1,003,480806,048535,708265,752299,380425,288
Tangible Book Value Per Share
12813.6710292.616840.583393.453822.855430.60
Machinery
-32,81932,71730,61121,07819,165
Construction In Progress
-4,591201.95236.841,6431,276